Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 691751 + itraconazole is an investigational combination used in clinical pharmacokinetic studies to assess drug-drug interaction. BI 691751 is a **small molecule inhibitor of Leukotriene A-4 hydrolase (LTA4H)**, developed primarily for cardiovascular indications such as atherosclerosis. Itraconazole is a well-established antifungal agent and a potent inhibitor of **CYP3A4** and **P-glycoprotein (P-gp)**, commonly used experimentally to evaluate the impact of metabolic and transporter inhibition on investigational drugs. The combination is used to gauge the changes in relative bioavailability, pharmacokinetics, safety, and tolerability of BI 691751 when its metabolism and transport are inhibited by itraconazole.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BI 691751 + itraconazole.